Fremman Capital (“Fremman”) is pleased to announce the acquisition of a majority stake in DIESSE Diagnostica Senese (“DIESSE”), a leading Italian producer of innovative diagnostic systems and dedicated reagents for the specialty In-Vitro Diagnostics (IVD) market. As part of the transaction, DIESSE’s management team will retain a meaningful minority stake and continue to steer the company’s growth.
Founded in 1980, DIESSE has become a global leader in the specialty IVD segment, focusing mainly on diagnostics for autoimmune and infectious diseases, and haematology measurement systems. The company offers one of the broadest portfolios of specialty immunoassay tests in the market, with more than 170 tests available on its fully automated instruments. The company operates a fully integrated business model, covering scientific R&D, instrument design, and biomaterial and reagent production in-house to ensure full quality control.
Headquartered in Monteriggioni (Siena, Italy), DIESSE operates out of a brand new, state of the art facility, named DIESSE Biotech Campus (“DBC”) — the largest R&D and biotech production plant dedicated to IVD in Italy — and employs 230 people. DIESSE’s customer base is comprised of clinical laboratories, including general and specialized hospitals and private labs, with products distributed through a broad network of official distributors, and serving clients in over 100 countries worldwide.
The global specialty diagnostics market is expected to grow significantly in the coming years, driven by long-term secular tailwinds such as increasing life expectancy, growing incidence of autoimmune conditions, infectious diseases and other rare pathologies, and increased testing frequency globally. These dynamics align seamlessly with Fremman’s strategy to invest in essential goods and services, ensuring long-term value creation in resilient, high-demand sectors.
Massimiliano Boggetti, CEO of DIESSE said: “Over the past five years, we have invested more than 10% of our revenues into research and development, focusing on innovation in immune system diagnostics. With Fremman’s contribution, we aim to widely disseminate this innovation in the coming years, helping patients worldwide achieve better diagnoses and more effective treatment”.
Edward Chandler, Founding Partner at Fremman, added: “We are delighted to partner with and support DIESSE’s outstanding management team and build on the company’s impressive track record of innovation and growth. DIESSE is uniquely positioned within the recession-resistant IVD market, and we see significant opportunities to further internationalize the business and enhance its market leadership.”
About DIESSE
DIESSE is a leading Italian producer of specialty In-Vitro Diagnostics (IVD) solutions, offering instruments and reagents for autoimmunity, infectious diseases, and automatic haematology measurement systems. With over 170 specialty disease tests, DIESSE’s products are used by clinical IVD laboratories, hospitals, and private labs worldwide. The company is headquartered in Italy and distributes its products through a global network of distributors and direct sales representatives.
For more information, please visit https://www.DIESSE.it/en/
About Fremman Capital
Fremman Capital is a pan-European, mid-market investment firm with offices in London, Luxembourg, Madrid, Munich, and Paris. The firm partners with successful management teams to help transform businesses into multinational sustainable leaders. Fremman Capital’s team brings over a century of combined investment experience, with a mission to foster sustainable business growth that positively impacts society.
For more information, please visit https://fremman.com